Zoetis Gains EU Approval for Portela® to Treat Osteoarthritis Pain in Cats
Zoetis Receives EU Approval for Portela® (relfovetmab), the First Three-Month Monoclonal Antibody Therapy for Osteoarthritis Pain in Cats Zoetis Inc. (NYSE: ZTS), the world leader in animal health, today annonced that the European Commission has granted marketing authorization for Portela®…